REGN Q1 2026: Dupixent and EYLEA Drive Growth as Regeneron Streams Ahead with Otarmeni and a $3B Buyback

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reports first-quarter 2026 results, signaling continued momentum in immunology and ophthalmology alongside major pipeline and capital-allocation moves.

Quarterly snapshot: REGN delivers a multi-front quarter

Regeneron, ticker REGN, posted first-quarter 2026 revenue of $3.6 billion, up 19% from the prior-year period. The standout top-line performance rides on Dupixent, the broad immunology franchise acquired its own weather system in the press release, with global net sales of $4.9 billion (as reported by Sanofi)—a 33% year-over-year rise that underscores durable demand and a growing portfolio beyond oncology-adjacent news.

On the earnings line, GAAP earnings per share came in at $6.75, including a $0.82 negative impact from IPR&D amortization, while non-GAAP EPS was $9.47, with a $0.80 drag from IPR&D. In short, the portion of earnings tied to in-process R&D write-downs remains a meaningful cross-check against recurring profitability measures.

Within the product mix, EYLEA continues to contribute, with U.S. net sales up 52% to $468 million for the segment cited, though total EYLEA U.S. net sales were reported as $941 million in a separate line. Dupixent remains the dominant engine, securing broad-welt demand and contributing to the strong top-line growth profile for the quarter.

Regeneron also highlighted regulatory and product-milestone news: EYLEA HD received FDA approval as the first and only injectable anti-VEGF option with dosing intervals up to five months for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Dupixent gained FDA and European Commission approvals for younger children with chronic spontaneous urticaria (CSU) and FDA approval for allergic fungal rhinosinusitis (AFRS). And in gene-therapy news, Otarmeni (lunsotogene parvec) was approved by the FDA as the first and only gene therapy for a genetic hearing loss, with Regeneron signaling a U.S. program to provide Otarmeni for free.

Strategically, Regeneron also announced a new $3.0 billion share repurchase program, signaling confidence in the business and capital allocation discipline even as it expands its portfolio and pipeline—an important signal for equity holders amid a complex pricing and reimbursement backdrop.

What this signals for REGN and its peers

From a framing perspective, the quarter reinforces a two-speed company: a high-visibility, high-margin immunology franchise with Dupixent driving the bulk of the earnings surge, and a robust ophthalmology franchise with EYLEA contributing meaningful, though more variable, revenue streams. The non-GAAP EPS of $9.47 versus GAAP EPS of $6.75 reflects, in part, the typical IPR&D accounting delta investors watch to gauge true operating efficiency versus accounting adjustments. The absence of a disclosed, concrete revenue forecast aside from a business update means traders will calibrate 2026 expectations against evolving pipeline milestones rather than a formal guidance print this quarter.

Analysts will parse the earnings against their EPS consensus estimates to gauge whether this quarter constitutes a bona fide earnings surprise or a confirmation of the durability in Regeneron’s mix. In practice, the durable Dupixent trajectory—paired with FDA/EC label expansions—suggests continued resilience in the near term, even as the company navigates pricing dynamics and payer strategies in the U.S. and abroad.

On the innovation front, Otarmeni adds a new regulatory chapter to Regeneron’s gene-therapy ambitions, complementing a pipeline that reportedly spans nearly 50 candidates. If Otarmeni proves scalable, it could provide meaningful upside optionality, particularly if early-adopter pricing and access logistics align with payer expectations. For sector peers, the message is clear: portfolio diversification into long-acting biologics, paired with selective gene-therapy bets, remains the recipe for multi-year growth, even as near-term margin commentary remains entangled with one-time accounting items and R&D timing.

Capital allocation and near-term posture

The new $3.0 billion share repurchase program signals a capital-return stance that complements a growth profile dependent on aging franchises and an expanding late-stage pipeline. In markets where drug pricing and access remain political flashpoints, a buyback can provide a measured signal of confidence to investors without compromising ongoing investment in R&D and late-stage registrations.

With earnings framed by EPS metrics—GAAP and non-GAAP—and with no explicit revenue forecast detailed in the release, market participants will likely await the next earnings call for updated guidance. In the meantime, Regeneron’s ability to sustain double-digit revenue growth alongside significant progress in regulatory approvals bodes well for REGN’s longer-term EPS trajectory, even if near-term prints are shaped by one-off IPR&D charges and evolving reimbursement landscapes.

Takeaways for investors and the ecosystem

REGN’s Q1 strength is anchored by Dupixent’s continued demand and regulatory expansion, underpinning the EPS narrative even as IPR&D adjustments cloud the pure operating earnings picture.
EYLEA, while still contributing, shows a more nuanced dynamics between HD variants and overall ophthalmology sales, illustrating the complexity of franchise performance across geographies and product variants.
Regeneron’s pipeline depth and recent regulatory milestones—especially Otarmeni—highlight optionality that could lift the earnings trajectory if adoption and pricing align with payer expectations.
The announced buyback supports equity value but will need to be weighed against the company’s ongoing investment needs as it scales its late-stage portfolio and commercialization capabilities globally.
Analysts will await next-period guidance and any updates to EPS consensus expectations to determine whether this quarter constitutes an earnings surprise or a solid execution narrative that vindicates the current multiple.

Bottom line

REGN’s first-quarter cadence underscores a company that can juggle a robust immunology franchise with meaningful pipeline optionality and disciplined capital allocation. The results reinforce the durability of Dupixent as a cornerstone asset and validate the strategic push into gene therapy with Otarmeni, even as pricing and access frameworks add a continuous layer of near-term challenge. For investors tracking EPS, earnings surprises, and revenue forecasts in large-cap biopharma, Regeneron provides a compelling case study in portfolio balance—where a high-growth revenue driver coexists with an earnings framework that still leans on one-time accounting items to paint a complete picture.